Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Supplement study seeks to build stronger bodies naturally

NCT ID NCT07502924

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a daily supplement called geranylgeraniol (GG) can improve muscle strength, body composition, and exercise capacity in healthy, physically active adults aged 30 to 60. About 70 participants will be randomly assigned to receive either a placebo, 150 mg, or 300 mg of GG daily for 8 weeks. Researchers will measure changes in strength, muscle endurance, and fat-free mass at the start, week 4, and week 8.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Between 30 and 60 years old. * Body mass index values will range from \>18.5 and \<29.9 kg/m2 * Subject agrees to maintain their existing dietary patterns throughout the study period. * Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day. * Is physically active, defined as at least 30 min of moderate exercise on at least 4 days a week. * Avoid consumption of pomegranate juice and avoid consumption of CoQ10, vitamin B3 and its precursors, L-carnitine, MK-4 * Subject is willing and able to comply with the study protocol. * Subject has given voluntary, written, informed consent to participate in the study. Exclusion Criteria: * BMI \<18.5 or \> 29.9 kg/m2 * Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease, kidney disease, renal failure, or has dialysis performed on regular intervals, Type I or Type II diabetes (determined as fasting blood glucose \> 126 mg/dL), thyroid disease, liver disease or some form of clinically diagnosed hepatic impairment, immune disorder (i.e., HIV/AIDS), or neurological condition or disease. * Diagnosed with any affective disorder or other psychiatric disorder that required hospitalization in the prior year. * History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). * Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) * Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism * Has donated blood in past 60 days * Diagnosed with or being treated for any endocrinological disorder and/or taking hormone boosting supplements (e.g. herbs) or hormone replacement therapy (prescribed/doctor ordered or not) * Had CoQ10 supplement in past 30 days. Had steroid medication one month before starting the study * Currently prescribed for the first time a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) and/or a hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, - Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months * Current smoker (average of \> 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine * Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to impact energy expenditure or weight loss (caffeine doses \<300 mg/day is permissible) * Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome * Women who are pregnant, planning to become pregnant, or lactating currently or within the past six months * Have a known sensitivity or allergy to any of the study products * History of alcohol or substance abuse in the 12 months prior to screening * Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol * Has participated in other clinical trials focused on physical and muscle performance within the last year * They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study * Individuals who regularly compete as part of sanctioned athletic activities or those individuals who regularly train more than 360 minutes of exercise per week * Recent history (\<3 months) of exercise training or weight loss (\> 5%) * Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Body composition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lindenwood University Exercise and Performance Nutrition Laboratory

    RECRUITING

    Saint Charles, Missouri, 63301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.